Sedatives

ICM announces deal with Neomille to design plant in Brazil

Retrieved on: 
Tuesday, August 3, 2021
Alcohols, Sedatives, Chemical substances, Ethanol fuel, Ethanol, Distillers grains, Corn ethanol, Maize

The greenfield plant will deliver a corn grinding capacity of 3,400 MT daily and produce over 500 MLPY of anhydrous ethanol or 540 MLPY of hydrous ethanol.

Key Points: 
  • The greenfield plant will deliver a corn grinding capacity of 3,400 MT daily and produce over 500 MLPY of anhydrous ethanol or 540 MLPY of hydrous ethanol.
  • Its production output will also include 23 MLPY of corn oil, in addition to 390,000 MT per year of DDGS.
  • ICM is proud to offer process design and technologies that allow Neomille to expand its production potential while serving the environment, said Issam Stouky, ICMs Director of Global Business Development.
  • Neomille represents a major investment by Cerradinho Bioenergia in advancing corn-based ethanol and animal feed in Brazil.

ICM announces deal with Neomille to design plant in Brazil

Retrieved on: 
Tuesday, August 3, 2021
Alcohols, Sedatives, Chemical substances, Ethanol fuel, Ethanol, Distillers grains, Corn ethanol, Maize

The greenfield plant will deliver a corn grinding capacity of 3,400 MT daily and produce over 500 MLPY of anhydrous ethanol or 540 MLPY of hydrous ethanol.

Key Points: 
  • The greenfield plant will deliver a corn grinding capacity of 3,400 MT daily and produce over 500 MLPY of anhydrous ethanol or 540 MLPY of hydrous ethanol.
  • Its production output will also include 23 MLPY of corn oil, in addition to 390,000 MT per year of DDGS.
  • ICM is proud to offer process design and technologies that allow Neomille to expand its production potential while serving the environment, said Issam Stouky, ICMs Director of Global Business Development.
  • Neomille represents a major investment by Cerradinho Bioenergia in advancing corn-based ethanol and animal feed in Brazil.

Marinus Pharmaceuticals Submits New Drug Application (NDA) to FDA for Ganaxolone for the Treatment of Seizures Associated with CDKL5 Deficiency Disorder and Provides Pipeline Update

Retrieved on: 
Tuesday, August 3, 2021
Biotechnology, FDA, Pharmaceutical, Health, Chemical compounds, Anticonvulsants, GABAA receptor positive allosteric modulators, Orphan drugs, Ganaxolone, Pregnanes, Sedatives, Health care, Health, CDKL5 Deficiency Disorder, Ganaxolone, Marinus Pharmaceuticals, CDKL5 DEFICIENCY DISORDER, GANAXOLONE, MARINUS PHARMACEUTICALS

We look forward to working with the FDA in their review process and remain focused on preparing for the anticipated U.S. launch.

Key Points: 
  • We look forward to working with the FDA in their review process and remain focused on preparing for the anticipated U.S. launch.
  • Ganaxolone was generally well-tolerated with a safety profile consistent with previous clinical trials, with the most frequent adverse event being somnolence.
  • Marinus received Rare Pediatric Disease (RPD) Designation from the FDA for ganaxolone for the treatment of seizures associated with CDD in July 2020.
  • Further details are available in Marinus press release distributed August 3, 2021 (Marinus Pharmaceuticals Announces Exclusive Collaboration with Orion Corporation for European Commercialization of Ganaxolone).

Braxia Scientific Provides Corporate Update and Reports Fiscal Fourth Quarter and Full-Year 2021 Financial Results

Retrieved on: 
Friday, July 30, 2021
Psychoactive drugs, Drugs, Health sciences, Antidepressants, General anesthetics, Arylcyclohexylamines, Nicotinic antagonists, Sedatives, Ketamine, Therapy, Bipolar disorder, Mental health

Through its global leading researchers and experienced implementation team, Braxia Scientific has established its presence in the mental health industry.

Key Points: 
  • Through its global leading researchers and experienced implementation team, Braxia Scientific has established its presence in the mental health industry.
  • Braxia Health is the first to offer novel Ketamine therapy, including intravenous therapy, to patients in a private clinical setting in Quebec.
  • In June 2021, the Company announced that Chief Medical and Scientific Officer Dr. Joshua Rosenblat, will initiate a first-of-its-kind ketamine clinical trial to treat bipolar depression.
  • "Braxia Scientific has achieved significant milestones to date, and we are picking up the pace," noted CEO Dr. Roger McIntyre.

Braxia Scientific CEO, Chief Medical Officer Awarded $918,000 by Canadian Government to Study Benefits of Integrating Ketamine with Cognitive Behavioural Therapy to Reduce Suicidality

Retrieved on: 
Wednesday, July 28, 2021
Psychoactive drugs, Drugs, Clinical medicine, Sedatives, Psychiatric diagnosis, Addiction, Addiction medicine, Cognitive behavioral therapy, Ketamine, Major depressive disorder, Behaviour therapy, Suicide

The funding will be used to evaluate the effectiveness of intravenous ketamine, in combination with internet-based cognitive behavioural therapy (iCBT), to rapidly reduce suicidality in persons with depression, when compared to iCBT alone.

Key Points: 
  • The funding will be used to evaluate the effectiveness of intravenous ketamine, in combination with internet-based cognitive behavioural therapy (iCBT), to rapidly reduce suicidality in persons with depression, when compared to iCBT alone.
  • It is separately reported in the biomedical literature that cognitive behavioural therapy may also reduce suicidality, but requires several weeks to months before reductions in suicidality are significant.
  • "Integrating ketamine with CBT provides an opportunity to rapidly reduce suicidality and sustain the effect over the long term.
  • Braxia Scientific is a medical research company with clinics that provide innovative ketamine treatments for persons with depression and related disorders.

Ketamine One Advances Research Capabilities via Controlled Substance Dealers Licence Application

Retrieved on: 
Wednesday, July 28, 2021
Psychoactive drugs, Drugs, Neurochemistry, Antidepressants, NMDA receptor antagonists, Dissociative drugs, Nicotinic antagonists, Sedatives, Ketamine, Nutraceutical, Psychedelic drug

The audits will enable KGK to conduct clinical trials in the areas of psychedelics and nutraceuticals, among other substances of study.

Key Points: 
  • The audits will enable KGK to conduct clinical trials in the areas of psychedelics and nutraceuticals, among other substances of study.
  • Todays announcements are further evidence of the synergies between our growing clinic network and our contract research offerings, said Ketamine Ones Interim CEO, Adam Deffett.
  • We view this as a great opportunity to demonstrate their operational capabilities while also earning a new revenue stream from Ketamine One, added Mr. Deffett.
  • As a collective enterprise, Ketamine One is dedicated to helping solve the growing need for safe and accessible mental health therapy.

Klarisana Behavioral Health and Ketamine Centers Announces National Expansion Plan

Retrieved on: 
Thursday, July 22, 2021
Psychoactive drugs, Drugs, Clinical medicine, Chloroarenes, Euphoriants, Ketamine, Sedatives, Mental health, Intramuscular injection

This expansion includes an extension of robust behavioral health services to all treatment centers, as the company aims to increase the affordability and access to proper mental healthcare across all locations.

Key Points: 
  • This expansion includes an extension of robust behavioral health services to all treatment centers, as the company aims to increase the affordability and access to proper mental healthcare across all locations.
  • As demand for accessible ketamine treatment rises, Klarisana has become one of the most trusted names in the market.
  • Klarisana has pioneered the use of intramuscular ketamine therapy to treat mental health and chronic pain conditions since 2015.
  • Now operating seven outpatient clinics in Texas, Colorado, and New Mexico, Klarisana is poised to become the number one Behavioral Health and Ketamine Center in the United States by the end of 2021.

BetterLife-Carleton University Research Team Secure Mitacs Accelerate Funding to Study the Therapeutic Effect of TD-010 in Chronic Anxiety

Retrieved on: 
Thursday, July 22, 2021
Psychoactive drugs, GABAA receptor positive allosteric modulators, Hypnotics, Muscle relaxants, Sedatives, Anxiolytic, Neurochemistry, Benzodiazepine

TD-010 or dihydrohonokiol-B (DHH-B) is a compound that BetterLife is developing primarily for benzodiazepine dependency in addition to anxiety.

Key Points: 
  • TD-010 or dihydrohonokiol-B (DHH-B) is a compound that BetterLife is developing primarily for benzodiazepine dependency in addition to anxiety.
  • We thank Mitacs for the funding and Carleton Universitys team, headed by Dr. Argel Aguilar-Valles at the Department of Neuroscience, for being an ideal partner to help us realize this vision."
  • The high rate of resistance to benzodiazepine and SSRIs for chronic anxiety disorder indicates an urgent unmet need for alternative anxiolytic treatments.
  • Mitacs is a not-for-profit organization that fosters growth and innovation in Canada by solving business challenges with research solutions from academic institutions.

Ketamine One’s IRP Clinic Using Innovative NeuroCatch Platform to Measure Brain Function in Injured Veterans

Retrieved on: 
Thursday, July 22, 2021
Psychoactive drugs, Drugs, Neurochemistry, General anesthetics, Dissociative drugs, NMDA receptor antagonists, Nicotinic antagonists, Sedatives, Ketamine, Neurocognition, IRPS

IRP has been an early adopter of NeuroCatchs advanced brain-scanning technology to better understand brain health and neurocognitive function in patients since September of 2020.

Key Points: 
  • IRP has been an early adopter of NeuroCatchs advanced brain-scanning technology to better understand brain health and neurocognitive function in patients since September of 2020.
  • NeuroCatch is expected to remain a key part of IRPs service offering as Ketamine One expands its network to new veteran-centric markets across Canada.
  • Unique service offerings such as NeuroCatch help Ketamine Ones clinicians create more tailored treatment plans for patients, which can increase their effectiveness over time.
  • Platforms like NeuroCatch are also significant as Ketamine One embarks on embracing digital therapeutics as a core element of its competitive strategy.

PharmaTher Expands Psychedelic Patent Portfolio with Filing of U.S. Patent Application for Novel Ketamine Formulation

Retrieved on: 
Wednesday, July 21, 2021
Psychoactive drugs, Drugs, Neurochemistry, Antidepressants, Arylcyclohexylamines, Dissociative drugs, Nicotinic antagonists, Sedatives, Ketamine, Patent

The Companys intellectual property portfolio includes 19 granted patent and patent applications filed in over 150 countries.

Key Points: 
  • The Companys intellectual property portfolio includes 19 granted patent and patent applications filed in over 150 countries.
  • I am pleased with our continued dedication to becoming a leader of novel ketamine products and implementing a patent strategy that would protect our clinical development and commercialization initiatives.
  • The patent application, entitled Methods and Compositions of Ketamine Formulation for Intradermal Administration, describes the potential improvement and therapeutic value of ketamine by delivering it through the skin.
  • PharmaTher is positioning itself as an innovator of novel uses, formulations and delivery forms of ketamine.